Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non …

YK Chae, A Arya, W Iams, MR Cruz, S Chandra… - … for immunotherapy of …, 2018 - Springer
Immunotherapy is among the most rapidly evolving treatment strategies in oncology. The
therapeutic potential of immune-checkpoint inhibitors is exemplified by the recent hail of …

Recent developments in radiotherapy

DE Citrin - New England journal of medicine, 2017 - Mass Medical Soc
Recent Developments in Radiotherapy | New England Journal of Medicine Skip to main content
The New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …

PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial

V Narayan, JS Barber-Rotenberg, IY Jung, SF Lacey… - Nature medicine, 2022 - nature.com
Chimeric antigen receptor (CAR) T cells have demonstrated promising efficacy, particularly
in hematologic malignancies. One challenge regarding CAR T cells in solid tumors is the …

Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials

JM Unger, R Vaidya, KS Albain, M LeBlanc… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE Women have more adverse events (AEs) from chemotherapy than men, but few
studies have investigated sex differences in immune or targeted therapies. We examined …

Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study

A Pearce, M Haas, R Viney, SA Pearson, P Haywood… - PloS one, 2017 - journals.plos.org
Aim Chemotherapy side effects are often reported in clinical trials; however, there is little
evidence about their incidence in routine clinical care. The objective of this study was to …

Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3

HI Scher, MJ Morris, WM Stadler, C Higano… - Journal of Clinical …, 2016 - ascopubs.org
Purpose Evolving treatments, disease phenotypes, and biology, together with a changing
drug development environment, have created the need to revise castration-resistant prostate …

[PDF][PDF] Validity and reliability of the US National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO …

AC Dueck, TR Mendoza, SA Mitchell, BB Reeve… - JAMA …, 2015 - jamanetwork.com
Importance To integrate the patient perspective into adverse event reporting, the National
Cancer Institute developed a patient-reported outcomes version of the Common …

Integration of oncology and palliative care: a Lancet Oncology Commission

S Kaasa, JH Loge, M Aapro, T Albreht… - The lancet …, 2018 - thelancet.com
Full integration of oncology and palliative care relies on the specific knowledge and skills of
two modes of care: the tumour-directed approach, the main focus of which is on treating the …

Development and validation of the symptom burden questionnaire for long covid (SBQ-LC): Rasch analysis

SE Hughes, S Haroon, A Subramanian, C McMullan… - bmj, 2022 - bmj.com
Objective To describe the development and validation of a novel patient reported outcome
measure for symptom burden from long covid, the symptom burden questionnaire for long …

Adverse effects of low-dose methotrexate: a randomized trial

DH Solomon, RJ Glynn, EW Karlson, F Lu… - Annals of internal …, 2020 - acpjournals.org
Background: Low-dose methotrexate (LD-MTX) is the most commonly used drug for
systemic rheumatic diseases worldwide and is the recommended first-line agent for …